Napo Therapeutics
is headquartered in Milan, Lombardy. Massimo Mineo is the CEO of Napo Therapeutics. Napo Therapeutics has raised a total of $7.6M in funding. Napo Therapeutics has 1 followers on Owler. Napo Therapeutics has an estimated revenue of <$1M and an estimate of less <10 employees.Napo Therapeutics
is headquartered in Milan, Lombardy. Massimo Mineo is the CEO of Napo Therapeutics. Napo Therapeutics has raised a total of $7.6M in funding. Napo Therapeutics has 1 followers on Owler. Napo Therapeutics has an estimated revenue of <$1M and an estimate of less <10 employees.
CEO
Massimo Mineo
News
Jun 30, 2026
Newswire
Press Release: Napo Therapeutics : Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Apr 02, 2026
FinanzNachrichten
Napo Therapeutics: Jaguar Health, Inc.: Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Jan 12, 2026
Newswire
Press Release: Napo Therapeutics : Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
Jan 06, 2026
PR-Inside
Press Release: Napo Therapeutics : Article About Groundbreaking Results from Study of Jaguar Health's ...
Dec 15, 2025
PR-Inside
Press Release: Napo Therapeutics : Jaguar Health Announces Abstract Submission for Preliminary Data from ...
Dec 02, 2025
PR-Inside
Press Release: Napo Therapeutics : Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway ...
Nov 24, 2025
PR-Inside
Press Release: Napo Therapeutics : Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, ...
May 20, 2025
Newswire
Press Release: Napo Therapeutics : First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
Apr 29, 2025
FinanzNachrichten
Napo Therapeutics: Jaguar Health, Inc.: REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease and Short Bowel Syndrome with Intestinal Failure
Apr 08, 2025
PR-Inside
Press Release: Napo Therapeutics : Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at ...